BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21841495)

  • 1. Clinically significant venous thromboembolic complications in burn patients receiving unfractionated heparin or enoxaparin as prophylaxis.
    Bushwitz J; LeClaire A; He J; Mozingo D
    J Burn Care Res; 2011; 32(6):578-82. PubMed ID: 21841495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
    Marciniak CM; Kaplan J; Welty L; Chen D
    PM R; 2012 Jan; 4(1):11-7. PubMed ID: 22269449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
    Dudley RR; Aziz I; Bonnici A; Saluja RS; Lamoureux J; Kalmovitch B; Gursahaney A; Razek T; Maleki M; Marcoux J
    J Neurotrauma; 2010 Dec; 27(12):2165-72. PubMed ID: 20939698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin.
    Pariser JJ; Pearce SM; Anderson BB; Packiam VT; Prachand VN; Smith ND; Steinberg GD
    J Urol; 2017 Feb; 197(2):302-307. PubMed ID: 27569434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of an enoxaparin dosing calculator using burn size and weight.
    Faraklas I; Ghanem M; Brown A; Cochran A
    J Burn Care Res; 2013; 34(6):621-7. PubMed ID: 24043245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
    Lin H; Faraklas I; Saffle J; Cochran A
    J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
    Arnold JD; Dart BW; Barker DE; Maxwell RA; Burkholder HC; Mejia VA; Smith PW; Longley JM
    Am Surg; 2010 Jun; 76(6):563-70. PubMed ID: 20583509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF; Neuhart E
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.
    Sherman DG; Albers GW; Bladin C; Fieschi C; Gabbai AA; Kase CS; O'Riordan W; Pineo GF;
    Lancet; 2007 Apr; 369(9570):1347-1355. PubMed ID: 17448820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
    Amin AN; Lin J; Lenhart G; Schulman KL
    Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unfractionated heparin versus enoxaparin for venous thromboembolism prophylaxis in intensive care units: a propensity score adjusted analysis.
    Samuel S; Li W; Dunn K; Cortes J; Nguyen T; Moussa D; Kumar A; Dao T; Beeson J; Choi HA; McCullough LD
    J Thromb Thrombolysis; 2023 May; 55(4):617-625. PubMed ID: 37029256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous Thromboembolism Prophylaxis in Low Body Weight Critically Ill Patients.
    Knox H; Edwin SB; Giuliano C; Paxton RA
    J Intensive Care Med; 2024 May; 39(5):493-498. PubMed ID: 38111295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
    Argenta C; Ferreira MA; Sander GB; Moreira LB
    Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.
    Happe LE; Farrelly EM; Stanford RH; Sarnes MW
    J Thromb Thrombolysis; 2008 Oct; 26(2):125-31. PubMed ID: 18034323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practice Patterns of Venous Thromboembolism Prophylaxis in Underweight, Critically Ill Patients with Neurologic Injury.
    Betthauser K; Pope H; Gowan M; Human T
    Neurocrit Care; 2017 Aug; 27(1):96-102. PubMed ID: 28097621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Venous Thromboembolism Prophylactic Measures Post Coronary Artery Bypass Graft Surgery.
    Wilsey HA; Pandya K; Beavers C; Xiaoshu L; Ather A
    Am J Cardiovasc Drugs; 2019 Dec; 19(6):589-595. PubMed ID: 31203501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients.
    Singer GA; Riggi G; Karcutskie CA; Vaghaiwalla TM; Lieberman HM; Ginzburg E; Namias N; Lineen EB
    J Trauma Acute Care Surg; 2016 Dec; 81(6):1101-1108. PubMed ID: 27488490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.